NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global amyotrophic lateral sclerosis treatment market size is estimated to grow by USD 663.7 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 12.79% during the forecast period. Increase in incidence and prevalence of amyotrophic lateral sclerosis is driving market growth, with a trend towards increase in aging population.
However, high cost of treatment poses a challenge. Key market players include AB Science SA, Alkem Laboratories Ltd., Apotex Inc.
, Aquestive Therapeutics Inc., Biogen Inc., Brainstorm Cell Therapeutics Inc.
, CORESTEM Inc., Cytokinetics Inc., Denali Therapeutics Inc.
, Dr Reddys Laboratories Ltd., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc.
, Italfarmaco Holding SPA, Medindia Health, Mitsubishi Chemical Group Corp., Otsuka Holdings Co. Ltd.
, Revalesio Corp., Sanofi, Sun Pharmaceutical Industries Ltd., and Treeway BV.
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The global aging population is on the rise, with the proportion of individuals over 60 years expected to nearly double from 12% to 22% between 2015 and 2050, according to the World Health Organization (WHO). This demographic shift increases the risk of developing neurological disorders, including Amyotrophic Lateral Sclerosis (ALS), which is more common in the el.